Small biotechs who chose to partner with us
Adapting Deal Structures for a Small-Scale Cis-Targeted Immunotherapy Program
Julie Trulson of Asher Biotherapeutics discusses how Lonza was not only willing – but eager – to take on her team’s small-scale biotherapeutic manufacturing program, as well as the flexibility and expertise that went into building a proposal that was the right fit for Asher.
Laying the Foundation for Success in Small-Batch Protein Development
Julie Trulson of Asher Biotherapeutics discusses Lonza’s proactiveness in bringing on Asher’s cis-targeted immunotherapy program, the flexibility that the Lonza team displayed in outlining the program’s structure and project plan, and her hopes for Asher and Lonza’s relationship moving forward.
Expertise and Collaboration Foster Success in Biotherapeutic Manufacturing
Julie Trulson of Asher Biotherapeutics discusses her team’s process in choosing a CDMO for their small-scale immunotherapeutic manufacturing program, the value that Lonza’s technical experts have delivered for them, and the transparent, collaborative partnership built along the way.
Monoclonal antibodies at Corvus
Corvus is a small biotech developing a monoclonal antibody for oncology patients. Lonza started work with available capacity in Singapore and then transferring to Slough, UK. The product is currently in clinical trials.
Protein development at Levicept
Simon Westbrook had an idea for a complex fusion chimera protein he believed could have a profound impact on chronic pain and joint degeneration in osteoarthritis patients. Lonza worked with him early on and the molecule is now in Phase II.
Surrozen – complex bispecific antibodies targeting tissue regeneration
Surrozen’s President & CEO, Craig Parker, discusses how the expertise, resources and flexibility of Lonza have been fundamental in advancing its novel and complex bispecific antibody candidates that target the WNT pathway.
Tuning the Myeloid Compartment with a Best-in-Class CDMO
Alicia Levey and Kiren Khanduja of Pionyr Immunotherapeutics discuss the basis for selection of Lonza to meet Pionyr’s goals to rapidly develop a third lead candidate from the start and to scale-up manufacturing of two clinical-stage immuno-oncol-5ogy treatments after tech transfer.